{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T15:57:38Z","timestamp":1781366258005,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.bbmt.2018.05.017","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T12:15:07Z","timestamp":1526472907000},"page":"2101-2109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Nico","family":"Gagelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-3245","authenticated-orcid":false,"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Styczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.05.017_bib0010","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0015","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0020","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbmt.2012.05.015","article-title":"Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation","volume":"18","author":"Green","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bbmt.2018.05.017_bib0025","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/cid\/cix804","article-title":"Kinetics of double-stranded DNA viremia after allogeneic hematopoietic cell Transplantation","volume":"66","author":"Hill","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0030","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/cid\/ciu364","article-title":"Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European Group for Blood and Marrow Transplantation","volume":"59","author":"Ljungman","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"18","key":"10.1016\/j.bbmt.2018.05.017_bib0035","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/j.ejca.2009.08.010","article-title":"Antiviral prophylaxis in haematological patients: Systematic review and meta-analysis","volume":"45","author":"Yahav","year":"2009","journal-title":"Eur J Cancer"},{"issue":"23","key":"10.1016\/j.bbmt.2018.05.017_bib0040","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199112053252303","article-title":"Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation","volume":"325","author":"Goodrich","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003","article-title":"Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant","volume":"118","author":"Goodrich","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-118-3-199302010-00004","article-title":"Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial","volume":"118","author":"Winston","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0055","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.bbmt.2018.05.017_bib0060","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bbmt.2018.05.017_bib0065","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.bbmt.2018.05.017_bib0070","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Kharfan-Dabaja","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"25","key":"10.1016\/j.bbmt.2018.05.017_bib0075","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0085","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.2008.16.8450","article-title":"Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"27","author":"Raanani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0090","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Assessing risk of bias in included studies","author":"Higgins","year":"2011"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0095","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.bbmt.2018.05.017_bib0100","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jclinepi.2008.06.007","article-title":"AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program","volume":"63","author":"Chou","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0105","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0110","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0120","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0125","doi-asserted-by":"crossref","first-page":"S19eS481","DOI":"10.1016\/j.bbmt.2016.01.009","article-title":"Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT) in CMV-seropositive patients: a randomized, double-Blind, placebo-controlled, parallel-group phase 3 trial","volume":"22","author":"Marty","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0130","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0140-6736(94)91835-X","article-title":"Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation","volume":"343","author":"Prentice","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0135","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2005-09-3624","article-title":"Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation\u2014a randomized double-blind placebo-controlled study","volume":"107","author":"Boeckh","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0140","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.bmt.1703770","article-title":"Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation","volume":"30","author":"Burns","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0145","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0150","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V99.8.3050","article-title":"Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants","volume":"99","author":"Ljungman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0155","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1086\/367836","article-title":"Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation","volume":"36","author":"Winston","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.bbmt.2018.05.017_bib0160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0165","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2002-03-0993","article-title":"Late cytomegalovirus disease and mortality in allogeneic hematopoietic stem cell transplant recipients: importance of viral load and T cell immunity","volume":"101","author":"Boeckh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0170","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","article-title":"Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation","volume":"99","author":"Reusser","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0175","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1128\/JCM.42.3.1142-1148.2004","article-title":"Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR","volume":"42","author":"Boeckh","year":"2004","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.bbmt.2018.05.017_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0185","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V88.10.4063.bloodjournal88104063","article-title":"Cytomegalovirus pp65 antigenemia-guided treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study","volume":"88","author":"Boeckh","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0190","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1186\/s12879-017-2854-2","article-title":"Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients","volume":"17","author":"Robin","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1016\/j.bbmt.2018.05.017_bib0195","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jcyt.2014.02.010","article-title":"The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches","volume":"16","author":"Jain","year":"2014","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0200","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/infdis\/153.3.478","article-title":"Risk factors for cytomegalovirus infection after human marrow transplantation","volume":"153","author":"Meyers","year":"1986","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bbmt.2018.05.017_bib0205","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood-2007-01-069294","article-title":"Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis","volume":"110","author":"Marty","year":"2007","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bbmt.2018.05.017_bib0210","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC Trial)","volume":"35","author":"Kr\u00f6ger","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bbmt.2018.05.017_bib0215","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.bbmt.2017.08.027","article-title":"Comparison of different rabbit anti-thymocyte globulin formulations in allogeneic stem cell transplantation: systematic literature review and network meta-analysis","volume":"23","author":"Gagelmann","year":"2017","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118302696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118302696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:05:10Z","timestamp":1761059110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118302696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1083879118302696"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.017","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}